Relief Therapeutics provides update from collaboration partner, ACER Therapeutics on commercial launch activities for Olpruva

Relief Therapeutics Holding SA, a biopharmaceutical company, announces that its collaboration partner, ACER Therapeutics, Inc., has provided an update on commercial launch activities for Olpruva. Relief Therapeutics entered a collaboration and license agreement with Acer Therapeutics Inc. in March 2021 for the worldwide development and commercialization of Olpruva (sodium phenylbutyrate; ACER-001) for oral suspension for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and maple syrup urine disease (MSUD). Acer reports that in support of the Olpruva launch in Q2 2023, the company is actively adding resources to establish its commercial and medical affairs presence in the US. As a part of its Olpruva commercialization strategy, Acer has recently introduced its patient support service, Olpruva Navigator by Acer Therapeutics, designed to assist UCD patients with support, access, education and patient adherence to treatment. Representatives will begin accepting prescriptions in late Q2 2023. Acer also reports the company is actively engaged in negotiations regarding access for Olpruva with the major commercial payers and state Medicaid organizations. According to Acer, the company has established a pricing strategy that reflects its commitment to deliver innovative treatments that are responsibly priced and accessible to those in need. Acer intends to price Olpruva competitively, at a significant discount to the currently available commercial product Ravicti, while implementing predictable pricing that will not increase beyond the rate of inflation. Acer indicated the company also plans to invest a portion of Olpruva revenue back into additional solutions aimed at improving outcomes for UCD patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!